Daniel P. Amos - Chairman and Chief Executive Officer
Analyst · Morgan Stanley
Thanks, Ken. Good morning, and thank you for joining us today. Let me start out by saying that I remain pleased with Aflac's financial performance. Our financial results for the second quarter and the first half of 2008 met or exceeded our expectations in both the United States and Japan. However from a sales perspective, I had expected Japan's, Aflac Japan's sales to produce better growth in the quarter, but I still believe that we can achieve our sales objective for the year. Most important, I continue to believe we are well positioned to achieve our objective for operating earnings per share for this year and 2009. Let me share some more thoughts about the quarter beginning without Aflac, Japan. It's the leading contributor to our consolidated financial statement, we were very satisfied with Alfa Japan's operating results in second quarter of 2008. Our top line was consistent with our budget for the year and the benefit ratio continued to improve as we expected. The persistency of our business was strong and we again produced solid pre-tax earnings growth. You may remember from the first quarter comments that we anticipated slower sales growth in the second quarter compared with Aflac Japan's 5% increase in the first quarter. In part that was because I knew how aggressively Aflac Japan pushed at the end of March. I felt that they had written some business in the first quarter that would otherwise occurred in the second quarter. Even though I believe second quarter sales results would be slower than the first quarter, I did not think we would have positive sales results. Instead, total new annualized premium sales declined 4.9% to 28.7 billion yen in the quarter. For the first six months new sales were $56.3 billion or 0.3% below the first half of 2007. One of the reasons for the sales decline was weaker cancer insurance sales than we anticipated. Cancer insurance sales in the second quarter of 2007 exceeded 10.8 billion yen and were the strongest that we have seen in a longtime. You may recall that cancer insurance sales a year ago benefited from a rush to purchase the product before the premium rate increase took effect. So we knew we were going be up against tough compressions. In addition our agents have been aggressively focused on selling our lower premium cancer upgrade product since March of this year. This separate policy bridge the coverage from the old product and our new Cancer Forte type product with daily out patient benefit and annuity for newly diagnoses patients and canceling in doctor referral benefits. This cancer upgrade policy has allowed us to leverage our policy holder base to increase sales. In the second quarter, we sold 94,500 of these upgrade policies. However, the average premium was much lower at 27,000 yen compared with the Cancer Forte average premium of about 50,500 yen per policy. We now realize, we must go back and concentrate on selling Cancer Forte, rather than upgrade policies which we will do. The good news is that the medical sales were up 8.7% for the second quarter and 13% for the first six months. Medical sales have benefited from Gentle EVER, our non standard medical product that we begin selling in August of 2007. Gentle EVER contributed 1.2 billion yen in sales or approximately 13% of the medial sales in the quarter. While we know this product appeals to a relatively narrow segment of the population, we've been pleased with the opportunity to extend our reach to new consumers and further segment the market for medical insurance. It's certainly been one component in our medical sales recovery. We continue to believe that sales of cancer and medical insurance will benefit from the new distribution channel, and we remain encouraged about the opportunities to sell through a significant number of banks in Japan. By the end of June, Aflac had already secured agreements with 154 banks to sell our products out of a total of 402 banks. That's a much greater number of selling agreements than our competitors, and it's more than we initially expected. In the second quarter, we sold 680 million yen in new business through the bank channel which is a 146.4% increase over the first quarter. In fact, June sales through the bank channel were greater than the entire first quarter. Although that's the tremendous increase over the first quarter Bank sales, we'd expected sales from the Bank channel to do even better. We believe slower than expected growth to this new channel primarily reflects the ongoing conservatism of some banks due to the regulatory environment. We're still very excited about the prospects of bank sales, because banks that have been introduced to our products are doing very well. In addition, we will begin selling the product through the bank channel in October. Also in response to the needs of banks, we developed a single premium product called which has been approved for the sales on this product called Santiso [ph] which has been approved for the sale by the FSA. This product provides lump sum payments upon the diagnosis of cancer, heart attack or stroke. It also has debt benefits. In addition, we have are very pleased that the national association of Shinkin banks has endorsed our Gentle EVER and weighs products to the membership of the 280 Shinkin banks. As I've said before, I believe bank sales in the fourth quarter should be 10 times the amount we rote in the first quarter. I still believe that's the case, and I expect the momentum in the bank channels to build in 2009 as well. Overall, we are confident in this channel and fully expect it to meet out long-term expectations. We're also looking forward to the opportunities to sell Cancer Forte products through our agreement with Japan Post Network. As I am sure you are aware where Japan Bus chose Aflac as the cancer insurance provider through their network company. Initially, we expected to sale through about 300 postal outlets almost... also beginning on October the first of this year. Next month, we will begin training 5000 Japan post workers. Needles to say, we continue to believe this is a great opportunity for both Japan Post and Aflac. I am sure most of you are aware that the FSA's recent issues of the business improvement order to the top 10 Japanese life insurance companies. We were very surprised and disappointed to receive an order, even though they are common. The order requires the company to enhance the process and then to report on the progress to the FSA. We took exception to the business improvement order because we believe it was unfair and unjust. We feel this for several reasons. First, Aflac Japan was one of few companies able to complete the five year claims review process by the date... deadline required by the FSA. Second, our average rate was low compared with others in the industry. During the five year review period we assessed more than 4.2 million benefit payments and determined that our average rate was 0.47%, which means that 99.53 of the benefits were paid properly. Since then we have lowered the average rate by half and we expect it to get even lower. Third, we are in close contact with the FSA throughout the process and completed all promised measures on schedule to correct the problem and to prevent reoccurrence. In our opinion it appears that in issuing the business improvement order, the FSA focused on the absolute number of cases and the overall yen amount associated with those cases, rather the considering the companies real average rate. On a positive side there was limited media coverage of the business improvement order and we do not expect any material impact on the business. Perhaps and most importantly this should now put the claims issue behind the industry Our marketing team in Japan has plans in place and all of Japan's offices or all of part of their bonus is tied to achieving 3 to 7% increases in sales for the year. Although our sales objective for the year is going to be more challenging then we initially thought, I believe we will achieve it. Now let me turn to our business in the United States, the top line of Aflac U.S. was consistent with the expectations and pre-tax earnings were better than our target. We were also pleased to see an improvement in persistency over the first quarter. Total new annualized premium sales were up 4.9% to 383 million. Although sales were below our annual target rate of 8% to 12% for the second quarter. I was encouraged to see a significant improvement following a very weak first quarter. For the first six months, total new annualized premium sales increased 2.6% to 736 million. We continue to be pleased with expansion our sales force. New age of recruitment has been solid this year and the second quarter we recruited more than 6700 new associates an increase of 4.2% for the six months recruits were up 6.3%. The average number of weekly producing sales associates also increased 6.3% in the second quarter after being up only 0.2% in the first quarter. We believe our success in increasing the number of producing sales associates has resulted from an enhanced training program and we've been implementing over the last few years. In addition to growth of our sales force the key indicators we used to measure our sales force activities continues to be very positive. For example the number of new payroll accounts rose 10.1% in the second quarter, following, an 8.5% increase in the first quarter. The growth of payroll accounts opened by new agents rose a very strong 20.3% in the second quarter. Production from new associates was also very positive, rising 12% in the second quarter. That leads us to believe that the fundamental approach to building and training an affective distribution team is still working and we continued it to be our main focus. I believe our strong payroll account growth suggest that employers are better understanding the benefits, Aflac brings to the table. They are seeing how Aflac's product help to provide health care options to there workers at an affordable price. We believe the improved acceptance of employers has benefited from the advertising message and also the new business to business initiatives; we discussed that the annuals meeting in May. And we are looking at the consumers buying pattern. The average revenue was premium per new customer is up for the first half of this year compared with the year ago. However during the same period, fewer employees took out coverage when we enrolled the new pay roll account, which is a problem and we are addressing it through better training. The obvious question is whether our new sales have been impacted by the slower economy. I think it's very safe to assume that some of our policy holders, potential customers and sales associates are feeling the pain of the current environment. Obviously we have operated in the challenging economics before. But it's been a long time since consumers have added deal with such short increases in gasoline and food prices. However, we don't believe this means that our fortunes are exclusively tied to the business cycle. As you've heard me say before, I believe the need for our products is actually more compelling when the economy weakens, because the financial risk to the household becomes more pronounced. The risks of serious illness or accidents don't change with the business cycle. But coping with rising household expenses, even more of a drain on the family's finances when a healthcare occur... event occurs. That's exactly where our products can provide value to the average American household. In this environment, it's up to us to understand the circumstances that existing and potential customers are facing and make sure that our message is appropriate and our products are affordable. We now that people don't wake up in the morning, and suddenly come to the realization that they need an extra layer of protection, especially in this challenging economy. It's our job to identify potential customers and inform them of the possible risk and then help mitigate those risks through the sale our products. You will recall that we held a national training day for our field force in the first quarter to intensify and coordinate our message in this current economy. One of the adjectives of that day was to train our sales force on how to sell our products in a weak economy. We have incorporated that message into our ongoing field training. Earlier this month, we released a commercial that speaks directly to the challenges consumers face and why Aflac's products are important in this type economy. We're doing what we believe is appropriate to support our sales force and customizing our training and tools to suit the current needs. While the weak economy, would have made it more challenging to sell, it's actually made it easier to recruit. The reason is that when unemployment people cannot find salary jobs, they are willing to try commissions that they normally would have not done. As I mentioned in the press release, it will clearly be difficult to achieve the minimum of 8% for this year when we need 12.5% for the second half. However, I can assure you that our sales director and eight territory directors are all pushing hard to improve the sales result so they can make a bonus. Importantly, we continue to believe that the U.S. market is perfectly suited to our business. There are literally millions of potential payroll accounts and tens on millions of potential customers that can benefit from our products. On a consolidated basis, I'm pleased with our overall financial position. Clearly there's been a lot of investor focused on the balance sheet of financial companies recently, which is certainly something that we understand. I'm proud that Aflac's balance sheet was marked by highly rated investments. Despite the turmoil of the capital markets, we are confident that our time tested investment approach remains prudent and effective in the current environment. Even though we have seen a sharp rise in unrealized losses on the fixed income investments, they have primarily resulted from the widening of credits for it. Remember, that a widening of spreads benefits our income statement as we invest huge cash flows in Japan at a more attractive investment yields. Our outlook for this year remains 14% to 15% increase in operating per diluted share, before the effect of foreign currency. I have a high degree of confidence that we can achieve that target and we hope to grow with a high end of the range this year. As I mentioned in our analyst meeting in May, our modeling suggest that 13% to 15% increase in operating earnings per diluted share excluding the currency is reasonable goal for 2009. I am still focused on increasing operating earnings per share by at least 15% excluding the impact of through yen from my first 20 years of Chief Executive Officer. Beyond those 20 years, I still think we can produce another ten years of double-digit earnings growth. As we look to the future, we believe our strong earnings growth will continue to exemplify our underlying earnings tower of our insurance operations in the United States and Japan. It will also reflect our prudent approach to deploying access capital in way that benefits our shareholders. Ken? C: Kenneth S. Janke Jr.: Well thank you Dan. Let me just briefly go through some of the second quarter numbers beginning with Aflac Japan. Starting at the top line in yen terms, of revenues were 2.9% for the quarter. Investment income was down 0.7%, due primarily the impact of stronger yen on Aflac Japan's dollar denominated investment income. If you exclude the effect of the stronger yen, investment income was actually up 5% on a currency neutral basis. Of the annualized persistency rate excluding the annuities was 94.5% compared with 94.7 in the first half of 2007, that was consistent with our expectation. In terms of quarterly operating ratios, the benefit ratio continued to improve over last year. It was 61.9% in the quarter compared with 63.7% a year ago and excluding the impact from the weaker excuse me, the stronger Yen on investment income the benefit ratio was 61.5%. The expense ratio for the quarter was 19.9%, up from 18.9 in 2007. The higher expense ratio was budgeted and therefore expected and the increase primarily reflected additional marketing expenses, especially for ongoing preparation on the bank channel and increased IT expenses. Reflecting the lower benefit ratio and the higher expense ratio, the margin rows from 17.4% to 18.2% in the quarter. With the expansion of the margin, free cash, earnings were up 7.5% for the quarter in Yen and again excluding the impact of the stronger Yen-on-dollar denominated investment income, pre tax earnings were up 11.1% in the quarter. On the investment side, yields in Japan were a bit higher than they were in the first quarter. For instance, looking at the index of 20 year JGB's, the yields averaged 2.24% in the second quarter, up from 2.08% in the first quarter. The compounded yield for 20 year JGB right now is about 2.26%. For the quarter invested our cash flow in Yen securities at an average rate of 3.27%, including dollars the blended rate was 3.46%. Our portfolio yield at the end of June was 398, that's down 1 basis point from the end of March and 11 basis points lower that a year ago. The overall credit quality of the portfolio remains very high. On a consolidated basis securities rated double BB or lower are only 1.9% if the end of June, which was unchanged since the end of March. We did have one small addition to our below investment credit holdings in the quarter that was Sprint Capital Corp. That was down grade and had an amortized cost of $24 million. Turing the Aflac U.S., total revenues were up 8.4% in the quarter. The annualized persistency rate for the six months was 73.1% which was up significantly from the first quarter and only down slightly from a year ago. Looking at the operating ratios for the Aflac U.S., the benefit ratio was 52.8% in the quarter, compared with 53.1% a year ago. The expense ratio was unchanged at 31.3, therefore the profit margin increased to 15.9% compared with 15.6 a year ago. As a result pre-tax operating earnings for Aflac U.S. were up 11.1% in the quarter. In terms of U.S. investments the new money yield for the quarter was 729, up from 651 a year ago. The yield on the portfolio at the end of June was 7.04%, up 3 basis points from the first quarter in the year ago. Looking at some other line items for the quarter, excluding FAS 115, the ratio of debts to total capital was 15.9% at the end of June, a little change from the 16.0% of a year ago. Non insurance interest expense in the quarter was $6 million, compared to $5 million a year ago. In the company and another unallocated expenses, were $11 million in the quarter, up from $5 million a year ago. That increase primarily reflected a reduction in retirement expense in 2007 and then lower investment income in 2008 at the parent company level. On a consolidated basis that pre-tax operating profit margin rose from 16.6% to 17.2%. The after tax margin also increased, rising from 10.9% to 11.2%. The tax rate, as we expected was little changed, and was 34.7 versus 34.6 a year ago. As reported, operating earnings per diluted share rose 23.2% to a $1 that was consistent with the guidance we had given on our first quarter call. The stronger Yen increased operating earnings by $0.08 per share in the quarter and $.013 for the first six months of the year. So excluding the Yen's impact, operating earnings per share were up 13.4% for both the quarter and the first six months. Lastly let me comment on the outlook for the year. AS Dan mentioned we have reaffirmed our target of 14 to 15% increase in operating earnings per diluted share, before the impact of the Yen for 2008. That would translate to a target of $3.73 to $3.76, assuming the exact same average exchange rate as we experienced in 2007. However, as you now the yen is clearly much stronger than it was a year ago. And if the yen is averages 105 to 110 for the full year, we would expect reported earnings per share to be $3.86 to $3.98 on a diluted basis for 2008. Under that same yen scenario, third quarter operating earnings per share would likely be $0.98 to $1.01 per diluted share. The first call estimate this morning was a $1.01. For 2009, our objective is a 13 to 15% increase in operating earnings per diluted share before the impact at the yen. We would like to make sure that everyone has a chance to ask a question this morning, so please let limit yourself to one question, so that we can be faired everyone and we'll try to give back with you if you have additional questions. Christine, we'd now be happy open it up and take some questions. Question And Answer